Kritika Agarwal
Partner
Mumbai Practice Area
Sectors
I am passionate about law as its dynamic and ever-changing and there’s something new to take away from every deal.
Kritika Agarwal has over a decade of experience and is part of the Firm’s Corporate Group. Kritika’s practice focusses on advising multinational clients on acquisitions, divestitures, joint ventures, strategic alliances, and general corporate and commercial strategy.
WORK HIGHLIGHTS
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
-
On its acquisitions of several multiplex chains valued at US$ 108 mn
-
On its global acquisition of an Italian group with extensive operations in India for US$ 143 mn
-
On its joint venture in the pharmaceuticals sector
-
On the sale of its global braking and friction division for US$375 mn
-
On its acquisitions in the pharmaceuticals sector
-
On the sale of its surgical and infection prevention business valued at US$ 710 million
RECENT RECOGNITION
2024
2023
Asialaw Profiles
‘Rising Star’ for Corporate / M&A
IFLR1000
‘Rising Star Partner’ for M&A
Legal 500 Asia Pacific
‘Next Generation Partner’ for Corporate/M&A
IFLR1000
‘Rising Star Partner’ for M&A
Legal Era
Named a Gennext Leading Lawyer for Corporate / M&A
RECENT RECOGNITION
Asialaw Profiles
‘Rising Star’ for Corporate / M&A
IFLR1000
‘Rising Star Partner’ for M&A
Legal 500 Asia Pacific
‘Next Generation Partner’ for Corporate/M&A
IFLR1000
‘Rising Star Partner’ for M&A
Legal Era
Named a Gennext Leading Lawyer for Corporate / M&A